AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05118399
Drug: Bupivacaine Liposome 13.3 MG/ML [Exparel]
RxNorm normalized name: bupivacaine liposome 13.3 MG/ML [Exparel]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
Trial: NCT04835584
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Trial: NCT04835584
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Trial: NCT05526898
Drug: Triamcinolone Injection
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid
Trial: NCT00002184
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002184
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002184
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002184
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002184
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002184
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06426082
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take salbutamol 12 mg/day. 7 days week
Trial: NCT05822609
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.0 mg
Trial: NCT05332405
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
Trial: NCT05549791
Drug: Remimazolam Tosilate for Injection
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam Tosilate for Injection
Trial: NCT06026358
Drug: Tirbanibulin
RxNorm normalized name: TIRBANIBULIN
DrugBank: Tirbanibulin (DB06137)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: subjects receive 2,5 mgTirbanibulin in 250 mg ointment with daily administration of one single sachet on the left hand and 250mg ointment placebo on the right hand for 5 d in a single-blinded manner.
Trial: NCT06170918
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: remimazolam is given intravenously
Trial: NCT05824338
Drug: Spinal anesthesia for lumbar surgery: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally
Trial: NCT05824338
Drug: Spinal anesthesia for lumbar surgery: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The anesthesiologist will administer 3 mL of bupivacaine 0.5% plus fentanyl 15 mcg intrathecally.
Trial: NCT06463171
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off.
Trial: NCT05814640
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commonly used oral antipsychotics intervention therapy.
Trial: NCT05814640
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commonly used oral antipsychotics intervention therapy.
Trial: NCT05814640
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commonly used oral antipsychotics intervention therapy.
Trial: NCT05814640
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Commonly used oral antipsychotics intervention therapy.
Trial: NCT05814640
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commonly used oral antipsychotics intervention therapy.
Trial: NCT05814640
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commonly used oral antipsychotics intervention therapy.
Trial: NCT06140966
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
Trial: NCT06140966
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
Trial: NCT06140966
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
Trial: NCT06140966
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
Trial: NCT06140966
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by vein: days 1-4 of each Induction cycle
Trial: NCT06140966
Drug: epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by vein: days 1-4 of each Induction cycle
Trial: NCT06140966
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein: days 1-4 of each Induction cycle
Trial: NCT06140966
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by vein: day -1 of Transplant
Trial: NCT06140966
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
Trial: NCT06048341
Drug: Ropivacaine injection
RxNorm normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
Trial: NCT06048341
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Trial: NCT04572451
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation.
Trial: NCT04572451
Drug: BMS-986253
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation.
Trial: NCT05203055
Drug: Peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180μg/w
Trial: NCT05203055
Drug: pulse peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 180μg/w for 8 consecutive weeks and cessation for 4 weeks
Trial: NCT05158192
Drug: Diosmin/Hesperidin (90/10) 500 mg Test Drug
DrugBank: Hesperidin (DB04703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Medicinal Product
Trial: NCT04916522
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg once daily
Trial: NCT04866056
Drug: Jaktinib
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaktinib PO BID
Trial: NCT04866056
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacytidine SC
Trial: NCT05933187
Drug: Treatment A: Emraclidine 30mg IR tablets (reference)
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR oral tablets
Trial: NCT05933187
Drug: Treatment B: Emraclidine 30mg IR test tablets 1
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR oral tablets
Trial: NCT05933187
Drug: Treatment C: Emraclidine 30mg IR test tablets 2
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR oral tablets
Trial: NCT05933187
Drug: Treatment D: Emraclidine 30mg IR test tablets 3
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR oral tablets
Trial: NCT04782388
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive Staccato alprazolam at prespecified time-point.
Trial: NCT06016556
Drug: nirmatrelvir, ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single cohort
Trial: NCT06629428
Drug: Ublituximab
RxNorm normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive 48 weeks of treatment with ublituximab.
Trial: NCT05623280
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection around the areola with 2-4 points Indocyanine green with 2ml of 1.25mg/mL
Trial: NCT05088226
Drug: Ruxolitinib combined with Chidamide.
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide .~Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI , Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;
Trial: NCT05640817
Drug: Pentoxifylline 400 mg SR tablets
RxNorm normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a nonspecific phosphodiesterase inhibitor, was first considered in the treatment of peripheral vascular diseases
Trial: NCT05640817
Drug: cisplatin with standard hydration with normal saline
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT05226754
Drug: Diacerein
RxNorm normalized name: diacerein
DrugBank: Diacerein (DB11994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
Trial: NCT05068388
Drug: Z-Endoxifen
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-Endoxifen
Trial: NCT05532254
Drug: Aripiprazole 10 mg tablet
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: an immediate-release tablet containing 10 mg Aripiprazole
Trial: NCT04890561
Drug: Lemborexant
RxNorm normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lemborexant oral tablets.
Trial: NCT05074498
Drug: TB006
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion
Trial: NCT06630923
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
Trial: NCT06631612
Drug: ferric hydroxide polymaltose complex
RxNorm normalized name: ferric hydroxide
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive oral iron supplementation according to body weight every other day
Trial: NCT06631612
Drug: ferric hydroxide polymaltose complex
RxNorm normalized name: ferric hydroxide
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive oral iron supplementation dose according to body weight daily
Trial: NCT04844099
Drug: Dihydroartemisinin Piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as dihydroartemisinin (20mg) and piperaquine (160 mg)
Trial: NCT05887817
Drug: Finerenone
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
Trial: NCT05104788
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05104788
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
Trial: NCT05104788
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
Trial: NCT05070104
Drug: CPI-613
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250-1000mg/m2 -14 day cycle
Trial: NCT05070104
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg IV
Trial: NCT05104788
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
Trial: NCT04701060
Drug: Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative：Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；four cycles， operation postoperation 4-8weeks，Camrelizumab ：200mg， iv，d1 q2w；apatinib：250mg,po，qd，q2w；Up to one year
Trial: NCT05000450
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for lymphodepletion
Trial: NCT06278857
Drug: Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]
RxNorm normalized name: Dostarlimab-gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dosing regimen follows standard clinical care protocol comprising of 4 cycles every 3-weeks, a rest period of 34 weeks followed by 3 cycles every 6 weekly for a total of 7 cycles.
Trial: NCT04874610
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of methylprednisolone Prescribed per Standard of care
Trial: NCT06400056
Drug: Terbinafine
RxNorm normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved
Trial: NCT05000892
Drug: Sintilimab , Carboplatin, Nab-paclitaxel
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
Trial: NCT05274984
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
Trial: NCT05062083
Drug: 11C-MC1
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 20 mCi injected IV followed by PET scanning
Trial: NCT05062083
Drug: 11C-PS13
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 20 mCi injected IV followed by PET Scanning
Trial: NCT05424003
Drug: Semaglutide Pen Injector
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
Trial: NCT06629415
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image
Trial: NCT06629415
Drug: Indocyanine Green Drug
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
Trial: NCT04563338
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.